Case Report

Rheumatoid Meningoencephalitis: A Feared Condition in the Era of TNF Blockers

Fernando Figueroa Rodriguez, Kwon Minkyung, Sruthi Jinna, Sohail Farshad, and Francisco Davila

Beaumont Health, Department of Medicine, Royal Oak, MI, USA

Correspondence should be addressed to Fernando Figueroa Rodriguez; fernando.figueroarodriguez@beaumont.org

Received 18 May 2018; Revised 23 September 2018; Accepted 11 November 2018; Published 16 December 2018

Academic Editor: Suleyman Serdar Koca

Copyright © 2018 Fernando Figueroa Rodriguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Central nervous system (CNS) involvement in rheumatoid arthritis (RA) is uncommon, and most of the times, it is secondary to vasculitic processes or extra-articular rheumatoid nodules. Meningeal involvement is extremely rare [1, 2]. Meningoencephalitis after starting TNFs has been described very few times. The incidence of this condition varies ranging from 0.55% to 2% in patients with RA. There are not enough data concerning prognosis, but mortality has been reported as high as 70% [2, 3].

The novelty and importance of our case is fourfold: first of all, RME is an extremely rare condition as detailed above.

1. Case Presentation

A 52-year-old male with a history of rheumatoid arthritis (RA) presented with 3 months of right-sided frontal-parieto-temporal headaches with associated fevers and weight loss. 2 weeks prior to admission, he developed dysarthria and left-sided hemiparesis. He was diagnosed with RA 10 years before and was on adalimumab at the time.

Physical exam revealed left-sided facial droop with ipsilateral upper and lower extremities weakness and sensory deficit, and multiple rheumatoid nodules were noted. Laboratory studies revealed leukocytosis with neutrophilia, normocytic anemia, and markedly elevated inflammatory markers. Computerized tomography of the head revealed a right frontal hypodensity (Figure 1). Brain magnetic resonance revealed patchy leptomeningeal enhancement involving right frontal and temporal lobes associated with subcortical edema (Figure 2). Cerebrospinal fluid (CSF) cytology revealed normal glucose with elevated proteins and white blood cells. Cultures from both, CFS and blood, were negative for typical and atypical bacteria, fungi, viruses, and parasites. Brain biopsy was obtained and showed microglial activation and gliosis, suggesting no microorganisms grew from brain tissue culture (Figure 3).

At this point, RME was strongly suspected, so the patient was started on methylprednisolone. He was sent home with long-term steroid taper. On follow-up visits in the office, all signs and symptoms were noted to be resolved.

2. Discussion

Central nervous system (CNS) involvement in rheumatoid arthritis (RA) is uncommon, and most of the times, it is secondary to vasculitic processes or extra-articular rheumatoid nodules. Meningeal involvement is extremely rare [1, 2]. Meningoencephalitis after starting TNFs has been described very few times. The incidence of this condition varies ranging from 0.55% to 2% in patients with RA. There are not enough data concerning prognosis, but mortality has been reported as high as 70% [2, 3].
The incidence is 0.5 to 2%, and it is present in a male, making it even rarer. The patient's signs and symptoms resolved with treatment, which is noted to be in less than 30% of the cases. Lastly, this particular patient was on adalimumab, a TNF blocker, which is the center of our discussion and review.

Most CNS symptoms associated with RA are secondary to osseous compression and joint involvement. True inflammation secondary to RA is a rare and potentially treatable condition, whose pathogenesis remains uncertain but can present as a wide spectrum of diseases [1]:

(i) Leptomeningitis (presenting with mental status changes, gait imbalance, memory loss, behavioral changes, seizures, and paresis).

(ii) Pachymeningitis (presenting with headaches and cranial neuropathies caused by dural fibrosis).
(iii) Cerebritis and cerebral vasculitis are a possibility as well and share some of the symptoms already mentioned. The latter can lead to stroke-like symptoms and thrombosis.

All these conditions are characterized by the absence of organisms in CSF, cultures, and brain biopsy. Spinal fluid analysis might reveal lymphocytic pleocytosis, but it is not always present [4]. An increased level of proteins is characteristic but not specific [5, 6]. New inflammatory markers have been used to aid in diagnosis, specifically rheumatoid factor (RF) in CSF, which is strongly positive in these cases as well as inflammatory cytokines, including TNF alpha, interleukin (IL) 1-beta and IL-6, which are thought to play a central role in the pathogenesis and are often found to be elevated in CSF [7]. MRI with gadolinium contrast is quite helpful by revealing diffuse or patchy enhancement in meninges as well as high intensity lesions in the FLAIR sequence [8]. Ultimately, a brain biopsy is needed for final diagnosis, and any of the following findings are indicative [7, 9]:

(i) Thickened meninges with nodules and plaques
(ii) Rheumatoid nodules (commonly located in cranial meninges and choroid plexus)
(iii) Nonspecific meningeal inflammation (mainly a mononuclear infiltrate, particularly plasma cells, and less frequently necrosis and multinucleated giant cells)
(iv) Vasculitis (involving brain, spinal cord parenchyma, and meninges)

The differential diagnosis of RME is broad, particularly infectious etiologies due to the use of immunosuppressants, including tuberculosis and fungal infections. Malignancy and drug-induced meningitis are also considerations. The presence of serum anti-CCP antibodies may be helpful in making the diagnosis as well [10–14].

Overall, the preponderance of plasma cells helps distinguish RME from other connective tissue disorders [6–15].

Standard treatment of rheumatoid meningoencephalitis is not established. Medications reported as effective in rheumatoid meningoencephalitis are high-dose corticosteroids, cyclophosphamide, azathioprine, and mycophenolate. It is controversial whether corticosteroids alone are enough to induce remission. The combination of steroids and intermittent cyclophosphamide therapies were effective in some cases [15]. Rituximab alone or in combination with leflunomide has been a successful alternative to high-dose steroids [1, 16]. Some suggests early recognition and treatment with corticosteroid improves survival and mortality, while some reports suggest the opposite [8, 17].

In summary, rheumatoid meningoencephalitis is a poorly understood condition and extremely rare as detailed above. We encourage clinicians to use our case as reference to obtain guidance in diagnosing and managing this condition. We also urge them to report any related cases as this can serve as the basis to better understand it.

### Table 1: Overview of patients with rheumatoid meningitis and meningoencephalitis.

|                          | No exposure to TNF blockers | Exposure to TNF blockers |
|--------------------------|-----------------------------|--------------------------|
| Number of cases reported | 28                          | 12                       |
| Age, median              | 66                          | 59                       |
| Male (%)                 | 11 (39%)                    | 3 (27%)                  |
| Length of illness, median| 4.5 years                   | 10 years                 |
| Number of patients whose length of illness is greater than 10 years | 11 (39%)                  | 6 (55%)                  |
| Number of patients with active rheumatoid arthritis, n (%) | 9 (32%)                   | 6 (55%)                  |

**RA treatment**

|                       | No exposure to TNF blockers | Exposure to TNF blockers |
|-----------------------|-----------------------------|--------------------------|
| Methotrexate          | 14 (68%)                    | 9 (82%)                  |
| Corticosteroid        | 11 (39%)                    | 3 (27%)                  |
| TNF blocker used, n (%) | N/A                        | Adalimumab 4 (33%)       |
|                       |                            | Etanercept 1 (8.5%)      |
|                       |                            | Golimumab 1 (8.5%)       |

**Meningitis treatment**

|                | No exposure to TNF blockers | Exposure to TNF blockers |
|----------------|-----------------------------|--------------------------|
| Corticosteroid | 23 (82%)                    | 8 (73%)                  |
| Cyclophosphamide | 7 (25%)                    | 2 (18%)                  |
| Azathioprine    | 1                           | 1                        |
| Other treatments | MTX 4                       | Rituximab 1              |
|                 | TNF blockers                | Infliximab 1             |
| CSF RF positivity   | 2                           | 0*                      |
| CSF WBC, median     | 36                          | 69                      |
| CSF protein, median | 67                         | 67                      |
| CSF glucose, median | 58                         | 48                      |
| Positive biopsy or autopsy pathology | 19 (68%) | 6 (55%) |
| Good prognosis      | 19 (68%)                    | 7 (64%)                  |

*No author reported CSF RF results in the TNF blocker exposure group.

### 3. Literature Review

Several of the medications used to treat RA can potentially have a role in the pathogenesis of RME:

(i) Methotrexate (MTX) can cause rheumatoid nodulosis on the extremities as well as leptomeningitis, probably through induction of adenosine synthesis [1].

(ii) TNF alpha has also been associated with the development of accelerated nodulosis [1, 2]. It has been postulated that TNF blockers may promote development of rheumatoid meningitis via accelerated nodulosis or other unknown mechanisms [3, 18].

For the potential association between TNF blockers and rheumatoid meningoencephalitis, we conducted a literature search from articles published in Medline from 2000 onwards and limited to English. We found 39 cases of
rheumatoid meningitis or meningoencephalitis. There were 39 case reports of meningitis/meningoencephalitis (MME) related to rheumatoid arthritis since 2001; results are as follows (Table 1):

(i) 64% were female; 36% were male
(ii) Median age was 64 years at the time of MME diagnosis
(iii) Median duration of RA was 10 years at the time of MME diagnosis
(iv) 11 out of 39 patients (28.2%) were exposed to TNF blocker prior to presentation

87% of patients received brain MRI, meanwhile only 64% of the patients underwent brain biopsy for diagnosis. All patients who had brain MRI showed enhancement.

Treatment was attempted with high-dose corticosteroids in most patients (82%). Cyclophosphamide, azathioprine, or rituximab were also used at a lesser degree. Due to the small number of cases, an association between the treatment agent and outcome was not able to be assessed.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] A.-C. M. L. Huys, P.-A. Guerne, and J. Horvath, “Rheumatoid meningitis occurring during adalimumab and methotrexate treatment,” *Joint Bone Spine*, vol. 79, no. 1, pp. 90–92, 2012.

[2] P. J. Kerstens, A. M. Boerbooms, M. E. Jeurissen, J. H. Fast, K. J. Assmann, and L. B. van de Putte, “Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases,” *Journal of Rheumatology*, vol. 19, no. 6, pp. 867–871, 1992.

[3] R. C. Chou, “Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab,” *Annals of the Rheumatic Diseases*, vol. 65, no. 8, pp. 1114–1116, 2006.

[4] N. Akin, C. Krishna, L. Bridges, J. Paul, N. Sofat, and B. Moynihan, “Rheumatoid Meningitis, a difficult case,” *Practical Neurology*, vol. 16, no. 4, p. 255, 2016.

[5] B. Roy, D. F. Uphoff, and I. E. Silverman, “Rheumatoid meningitis presenting with multiple stroke like episodes,” *JAMA Neurology*, vol. 72, no. 9, pp. 1073–1076, 2015.

[6] A. M. Parsons, L. A. Zuniga, J. M. Hoaxworth et al., “Rheumatoid meningitis,” *Neurologist*, vol. 23, no. 3, pp. 83–85, 2018.

[7] S. E. Jones, N. A. Belsley, T. C. McLoud, and M. E. Mullins, “Radiologic-pathologic conference of the Massachusetts general hospital,” *American Journal of Roentgenology*, vol. 186, no. 4, pp. 1181–1183, 2006.

[8] P. Bourgeois, J. Rivest, and C. Bocti, “Rheumatoid meningitis presenting with stroke-like episodes,” *Neurology*, vol. 82, no. 17, pp. 1564–1565, 2014.

[9] M. J. Aguilar-Amat, M. J. Abenza-Abildúa, F. Vivancos et al., “Rheumatoid meningitis mimicking progressive supranuclear palsy,” *The Neurologist*, vol. 17, no. 3, pp. 136–140, 2011.

[10] R. Koide, A. Isoo, K. Ishii, A. Uruha, and M. Bandoh, “Rheumatoid leptomeningitis: rare complication of rheumatoid arthritis,” *Clinical Rheumatology*, vol. 28, no. 9, pp. 1117–1119, 2009.

[11] J. Hawboldt and M. Bader, “Intramuscular methotrexate-induced aseptic meningitis,” *Annals of Pharmacotherapy*, vol. 41, no. 11, pp. 1906–1911, 2007.

[12] J.-D. Cohen, C. Jorgensen, and J. Sany, “Leflunomide-induced aseptic meningitis,” *Joint Bone Spine*, vol. 71, no. 3, pp. 243–245, 2004.

[13] M. Ahmed, M. Luggen, J. H. Herman et al., “Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration,” *Journal of Rheumatology*, vol. 33, no. 11, pp. 2344–2346, 2006.

[14] N. Hegde, C. Gayomali, and M. W. Rich, “Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum?,” *Southern Medical Journal*, vol. 98, no. 5, pp. 564–566, 2005.

[15] J. Ryan and R. T. Keenan, “Rheumatoid arthritis presenting as rheumatoid meningitis: a case report,” *Case Reports in Internal Medicine*, vol. 4, no. 3, p. 17, 2017.

[16] A. E. Yücel, H. Kart, P. Aydin et al., “Pachymeningitis and optic neuritis in rheumatoid arthritis: successful treatment with cyclophosphamide,” *Clinical Rheumatology*, vol. 20, no. 2, pp. 136–139, 2014.

[17] L. Schmid, M. Müller, T. Treumann et al., “Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab,” *Arthritis and Rheumatism*, vol. 60, no. 6, pp. 1632–1634, 2009.

[18] T. Kato, K.-i. Hoshi, Y. Sekijima et al., “Rheumatoid meningitis: an autopsy report and review of the literature,” *Clinical Rheumatology*, vol. 22, no. 6, pp. 475–480, 2003.

[19] M. C. Duray, E. Marchand, S. Gohy, B. Weynand, B. De Coene, and P. Laloux, “Granulomatous meningitis due to rheumatoid arthritis,” *Acta Neurologica Belgica*, vol. 112, no. 2, pp. 193–197, 2012.
